Janux Therapeutics Inc. (JANX)
NASDAQ: JANX
· Real-Time Price · USD
22.89
-0.71 (-3.01%)
At close: Jun 23, 2025, 3:59 PM
22.88
-0.07%
After-hours: Jun 23, 2025, 05:51 PM EDT
-3.01% (1D)
| Bid | 22.77 |
| Market Cap | 1.35B |
| Revenue (ttm) | 9.34M |
| Net Income (ttm) | -77.74M |
| EPS (ttm) | -1.36 |
| PE Ratio (ttm) | -16.83 |
| Forward PE | -8.94 |
| Analyst | Buy |
| Ask | 25 |
| Volume | 506,051 |
| Avg. Volume (20D) | 971,424 |
| Open | 23.36 |
| Previous Close | 23.60 |
| Day's Range | 22.60 - 24.04 |
| 52-Week Range | 22.48 - 71.71 |
| Beta | 2.96 |
About JANX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol JANX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for JANX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Janux Therapeutics Inc. is scheduled to release its earnings on Aug 6, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
6 months ago
+11.64%
Janux Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
6 months ago
+48.98%
Janux Therapeutics shares are trading higher after the company announced updated interim clinical data for its JANX007 program in prostate cancer.
2 months ago · seekingalpha.com
Janux Therapeutics: Buying For The Promising Pipeline, Holding For The BuyoutJanux Therapeutics' lead program, JANX007, shows promising early results in prostate cancer, with significant PSA declines and no serious side effects reported. The company's strong financial position...